Home
Mercati
Grafici & Idee
Algo
Notizie
Store
Broker
Scarica
Calendario Economico
Segnali di Trading
Terminale Web
Digita
/
per cercare: @user, $symbol
Cerca
Accedi
Crea un account
Español
English
Русский
中文
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
ACIU
#6082
AC Immune SA
2.9
3
-0.34%
Settore:
Base:
Valuta di Profitto:
Intervallo Giornaliero
Intervallo Annuale
Variazione giornaliera
-0.34%
Variazione Mensile
-17.93%
Variazione di 6 mesi
+42.23%
Variazione Annuale
+14.45%
Chiusura Precedente
2.9
4
Open
2.9
3
Bid
Ask
Low
2.9
3
High
2.9
3
Volume
17
Mercati
Mercato Azionario Statunitense
Salute
ACIU
Open full chart
Financials
Overview
Estratto Conto
Statistics
Dividends
Quarterly
Annual
Income statement
Balance sheet
Cash flow
Value
Q4, 24
Total assets
—
Total liabilities
—
Total equity
—
Total liabilities & shareholders' equities
—
Total debt
—
Net debt
—
Notizie
AC Immune inicia ensayo de fase 1 de inhibidor NLRP3 penetrante cerebral
AC Immune inicia ensayo fase 1 de inhibidor NLRP3 que penetra cerebro
AC Immune begins phase 1 trial of brain-penetrant NLRP3 inhibitor
2026 Market Outlook: Focus On Pharma For Consistent Returns, Potential Skyrocketing Shares
AC Immune: Maintaining 'Buy' Rating On Next Steps For ACI-7104.056 Development In PD
Tesla and Rivian among market cap stock movers on Friday
AC Immune Trial Shows Early Signs Immunotherapy May Slow Parkinson's - AC Immune (NASDAQ:ACIU)
Las acciones de AC Immune suben tras datos positivos de ensayo para Parkinson
Acciones de AC Immune suben tras datos positivos en ensayo de Parkinson
AC Immune stock rises after positive Parkinson’s disease trial data
El tratamiento para el Parkinson de AC Immune muestra promesas en frenar la enfermedad
Tratamiento de AC Immune para Parkinson muestra promesa en frenar la enfermedad